Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials

Drug and Alcohol Dependence

Volumn 163, Issue , 2016, Pages 24-30

  DeWorsop, David ^a,b,c   Creatura, Gina ^a,b,c   Bluez, Grai ^a,b,c   Thurnauer, Halle ^a,b,c   Forselius Bielen, Kimberlee ^a,b,c   Ranganathan, Mohini ^a,b,c   Deaso, Emma ^a,b,c   Bhat, Jasra Ali ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Medication; Nonadherence; Noncompliance; Substance abuse; Telehealth; Videocalling

Indexed keywords

N (3 PYRIDAZINYL) 4 [3 (5 TRIFLUOROMETHYL 2 PYRIDINYLOXY)BENZYLIDENE] 1 PIPERIDINECARBOXAMIDE;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG USE; FEASIBILITY STUDY; HUMAN; MEDICATION COMPLIANCE; MORNING DOSAGE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMARTPHONE; TELEMONITORING; VIDEORECORDING; ADOLESCENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MARIJUANA ABUSE; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TELECONSULTATION; TELEMEDICINE; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEDICATION ADHERENCE; MIDDLE AGED; PILOT PROJECTS; REMOTE CONSULTATION; SMARTPHONE; TELEMEDICINE; YOUNG ADULT;

EID: 84969269123     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.02.045     Document Type: Article

References (55)

1. Acosta F.J., Hernandez J.L., Pereira J., Herrera J., Rodriguez C.J. Medication adherence in schizophrenia. World J. Psychiatry 2012, 2:74-82.
2. Alvarez-Jimenez M., Alcazar-Corcoles M.A., Gonzalez-Blanch C., Bendall S., McGorry P.D., Gleeson J.F. Online: social media and mobile technologies for psychosis treatment: a systematic review on novel user-led interventions. Schizophr. Res. 2014, 156:96-106.
3. Anderson A.L., Li S.H., Markova D., Holmes T.H., Chiang N., Kahn R., Campbell J., Dickerson D.L., Galloway G.P., Haning W., Roache J.D., Stock C., Elkashef A.M. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015, 150:170-174.
4. Armfield N.R., Gray L.C., Smith A.C. Clinical use of Skype: a review of the evidence base. J. Telemed. Telecare 2012, 18:125-127.
5. Blum K., Han D., Femino J., Smith D.E., Saunders S., Simpatico T., Schoenthaler S.J., Oscar-Berman M., Gold M.S. Systematic evaluation of compliance to prescribed treatment medications and abstinence from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS One 2014, 9:e104275.
6. Chesney M.A., Ickovics J.R., Chambers D.B., Gifford A.L., Neidig J., Zwickl B., Wu A.W. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments patient care committee & adherence working group of the outcomes committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12:255-266.
7. Choudhry N.K., Krumme A.A., Ercole P.M., Girdish C., Isaman D.L., Matlin O.S., Brennan T.A., Shrank W.H., Franklin J.M. Rationale and design of the randomized evaluation to measure improvements in non-adherence from low-Cost devices (REMIND) trial. Contemp. Clin. Trials 2015, 43:53-59.
8. Creary S.E., Gladwin M.T., Byrne M., Hildesheim M., Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease. Pediatr. Blood Cancer 2014, 61:1068-1073.
9. Crossland N.J. Understanding Non-Adherence 2011, (accessed on 7.24.15). http://www.appliedclinicaltrialsonline.com/understanding-non-adherence.
10. Dayer L., Heldenbrand S., Anderson P., Gubbins P.O., Martin B.C. Smartphone medication adherence apps: potential benefits to patients and providers. J. Am. Pharm. Assoc. 2013, 53:172-181.
11. DeFulio A., Silverman K. The use of incentives to reinforce medication adherence. Prev. Med. 2012, 55:S86-94.
12. Dimasi J.A. Cost of Developing a New Drug 2014, R&D Cost Study Briefing. Tufts Center for the Study of Drug Development.
13. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999, 35:S93-100. (Suppl).
14. Farmer K.C. Methods for measuring and monitoring medication regimen in clinical trials and clinical practice. Clin. Ther. 1999, 21:1074-1090.
15. Fenerty S.D., West C., Davis S.A., Kaplan S.G., Feldman S.R. The effect of reminder systems on patients' adherence to treatment. Patient Prefer. Adherence 2012, 6:127-135.
16. Fuller R.K., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., James K.E., Lacoursiere R.B., Lee K.K., Lowenstam I., Maany I., Neiderhiser D., Nocks J.J., Shaw S. Disulfiram treatment of alcoholism. JAMA 1986, 256:7.
17. Galloway G.P., Coyle J.R., Guillen J.E., Flower K., Mendelson J.E. A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones. J. Addict. Med. 2011, 5:170-174.
18. Garfein R.S., Collins K., Munoz F., Moser K., Cerecer-Callu P., Raab F., Rios P., Flick A., Zuniga M.L., Cuevas-Mota J., Liang K., Rangel G., Burgos J.L., Rodwell T.C., Patrick K. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int. J. Tuber. Lung Dis. 2015, 19:1057-1064.
19. Harrison V., Proudfoot J., Wee P.P., Parker G., Pavlovic D.H., Manicavasagar V. Mobile mental health: review of the emerging field and proof of concept study. J. Ment. Health 2011, 20:509-524.
20. Hinkin C.H., Hardy D.J., Mason K.I., Castellon S.A., Durvasula R.S., Lam M.N., Stefaniak M. Medication adherence in HIV-infected adults: effect of patient age cognitive status, and substance abuse. AIDS 2004, 18(Suppl. 1):S19-25.
21. Hinkin C.H., Barclay T.R., Castellon S.A., Levine A.J., Durvasula R.S., Marion S.D., Myers H.F., Longshore D. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007, 11:185-194.
22. Hoffman J.A., Cunningham J.R., Suleh A.J., Sundsmo A., Dekker D., Vago F., Munly K., Igonya E.K., Hunt-Glassman J. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am. J. Prev. Med. 2010, 39:78-80.
23. Iseman M.D., Cohn D.L., Sbarbaro J.A. Directly observed treatment of tuberculosis. N. Engl J. Med. 1993, 328:576-578.
24. Kofoed L., Kania J., Walsh T., Atkinson R.M. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am. J. Psychiatry 1986, 143:867-872.
25. Krueger K., Ruby D., Cooley P., Montoya B., Exarchos A., Djojonegoro B.M., Field K. Videophone utilization as an alternative to directly observed therapy for tuberculosis. Int. J. Tuber. Lung Dis. 2010, 14:779-781.
26. LeRouge C.M., Garfield M.J., Hevner A.R. Patient perspectives of telemedicine quality. Patient Prefer. Adherence 2015, 9:25-40.
27. Lee D., Mansi I., Bhushnan S., Parish R. Non-adherence in at-risk heart failure patients: characteristics and outcomes. J. Nat. Sci. 2015, 1:5.
28. Li Q., Lynen F., Wang J., Li H., Xu G., Sandra P. Comprehensive hydrophilic interaction and ion-pair reversed-phase liquid chromatography for analysis of di- to deca-oligonucleotides. J. Chromatogr. A. 2012, 1255:237-243.
29. Lucas G.M., Cheever L.W., Chaisson R.E., Moore R.D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 2001, 27:251-259.
30. Magidson J.F., Listhaus A., Seitz-Brown C.J., Safren S.A., Lejuez C.W., Daughters S.B. Can behavioral theory inform the understanding of depression and medication nonadherence among HIV-positive substance users?. J. Behav. Med. 2015, 38:337-347.
31. Matsui D. Strategies to measure and improve patient adherence in clinical trials. Pharm. Med. 2008, 23:289-297.
32. McRae-Clark A.L., Baker N.L., Sonne S.C., DeVane C.L., Wagner A., Norton J. Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence. J. Subst. Abuse Treat. 2015, 57:70-74.
33. Mirsaeidi M., Farshidpour M., Banks-Tripp D., Hashmi S., Kujoth C., Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. Eur. Resp. J. 2015, 46:871-874.
34. Moreira T.D., Signor L., Figueiró L.R., Fernandes S., Bortolon C.B., Benchaya M.C., Ferigolo M., Barros H.M.T. Non-adherence to telemedicine interventions for drug users: systematic review. Revista de Saúde Pública 2014, 48:521-531.
35. Nieuwlaat R., Wilczynski N., Navarro T., Hobson N., Jeffery R., Keepanasseril A., Agoritsas T., Mistry N., Iorio A., Jack S., Sivaramalingam B., Iserman E., Mustafa R.A., Jedraszewski D., Cotoi C., Haynes R.B. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. 2014, CD000011.
36. Novick D., Haro J.M., Suarez D., Perez V., Dittmann R.W., Haddad P.M. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010, 176:109-113.
37. Osterberg L.O., Blaschke T.B. Adherence to medication. N. Engl. J. Med. 2005, 353:487-497.
38. Roebuck M.C., Liberman J.N., Gemmill-Toyama M., Brennan T.A. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff. (Millwood) 2011, 30:91-99.
39. Sertkaya A. Examination of Clinical Trial Costs and Barrier for Drug Development. Eastern Research Group 2014, U.S. Department of Health and Human Services, Washington, D.C.
40. Shin P., Sharac J., Jacobs F. Provision of telemedicine services by community health centers. J. Public Health Inf. 2014, 6:e185.
41. Shiovitz T.M., Bain E.E., McCann D.J., Skolnick P., Laughren T., Hanina A., Burch D. Mitigating the effects of nonadherence in clinical trials. J. Clin. Pharmacol. 2015, (Epub ahead of print).
42. Smith D.L. Patient nonadherence in clinical trials: could there be a link to postmarketing patient safety?. Ther. Innovation Regul. Sci. 2012, 46:27-34.
43. Swartz M.S., Swanson J.W., Hiday V.A., Borum R., Wagner H.R., Burns B.J. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am. J. Psychiatry 1998, 155:226-231.
44. Swartz M.S., Swanson J.W., Hiday V.A., Borum R., Wagner R., Burns B.J. Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc. Psychiatry Psychiatr. Epidemiol 1998, 33(Suppl. 1):S75-80.
45. Swift R., Oslin D.W., Alexander M., Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J. Stud. Alcohol Drugs 2011, 72:1012-1018.
46. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin. Pharmacokinet. 1997, 32:345-356.
47. Vervloet M., Linn A.J., van Weert J.C., de Bakker D.H., Bouvy M.L., van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J. Am. Med. Inf. Assoc. 2012, 19:696-704.
48. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence: role of subject compliance. Arch. Gen. Psychiatry 1997, 54:737-742.
49. Volpp K.G., John L.K., Troxel A.B., Norton L., Fassbender J., Loewenstein G. Financial incentive-based approaches for weight loss: a randomized trial. JAMA 2008, 300:2631-2637.
50. Vrijens B., Urquhart J. Methods for measuring enhancing, and accounting for medication adherence in clinical trials. Clin. Pharmacol. Ther. 2014, 95:617-626.
51. Wade V.A., Karnon J., Eliott J.A., Hiller J.E. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS One 2012, 7:e50155.
52. Waldrop-Valverde D., Dong C., Ownby R.L. Medication-taking self-efficacy and medication adherence among HIV-infected cocaine users. J. Assoc. Nurses AIDS Care 2013, 24:198-206.
53. Wallwiener M., Wallwiener C.W., Kansy J.K., Seeger H., Rajab T.K. Impact of electronic messaging on the patient-physician interaction. J. Telemed. Telecare 2009, 15:243-250.
54. Weis S.E., Slocum P.C., Blais F.X., King B., Nunn M., Matney B., Gomez E., Foresman B.H. The Effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 1994, 330:1179-1184.
55. Wu Y.P., Hommel K.A. Using technology to assess and promote adherence to medical regimens in pediatric chronic illness. J. Pediat. 2014, 164:922-927.